primary IgA nephropathy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Primary IgA nephropathy confirmed by renal biopsy; 2.Age >= 18 years old; 3. 24-hour urinary protein quantification>0.5g/d; 4. Estimated glomerular filtration rate (eGFR)>30ml/min/1.73m^2 5. The patient or guardian voluntarily signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Systemic diseases that may lead to the deposition of mesangial immunoglobulin A (IgA), including but not limited to allergic purpura, systemic lupus erythematosus, herpetic dermatitis, ankylosing spondylitis, etc. 2. Combined with other kidney diseases, such as diabetes nephropathy, C3 glomerular disease, nephrotic syndrome, etc; 3. Active infection, severe liver dysfunction (Child Pugh C grade), congestive heart failure, and malignant tumors other than basal cell carcinoma within 5 years; 4. Allergic reactions to any ingredient in budesonide or budesonide enteric coated capsules, including severe hypersensitivity reactions, including allergic reactions, that have occurred with the use of other budesonide formulations; 5.Within the first 4 weeks of treatment with Dexmedetomidine enteric coated capsules, systemic hormone therapy (prednisone, methylprednisolone, etc.), immunosuppressive therapy (cyclophosphamide, cyclosporine, azathioprine, mycophenolic acid, calcineurin inhibitors, etc.), and biologic therapy targeting B cells (tacrolizumab, etc.) should be used; 6.Pregnant and lactating female patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of decreased AID and I a - C a levels compared to baseline in the 9th month; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of decreased levels of fecal IgA and Gd-IgA1 compared to baseline at each visit point; | — |
Countries
China
Contacts
Xiangya Second Hospital of Central South University